NCT03004287 2025-09-10
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
Phase 2 Active not recruiting
Clinical Trials
46 trialsNCT00869232 2025-06-29
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Active not recruiting
NCT04352205 2024-07-01
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Phase 2 Terminated
NCT02586038 2024-05-08
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
University of Turin, Italy
Phase 2 Completed
NCT02891811 2024-03-29
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT00054158 2022-10-03
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
Roswell Park Cancer Institute
Phase 2 Completed
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT00792142 2021-08-19
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT02128230 2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Terminated
NCT00538733 2021-05-24
T-BiRD
Weill Medical College of Cornell University
Phase 2 Completed
NCT00006890 2020-04-02
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Phase 2 Completed
NCT03608501 2020-01-14
IDEALL
Takeda
Phase 2 Withdrawn
NCT02410694 2019-12-13
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT00049374 2019-10-17
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 2 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT00064337 2018-08-09
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT00124579 2018-08-09
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Terminated
NCT01526694 2018-07-03
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
Azienda Ospedaliera di Bolzano
Phase 2 Completed
NCT00538824 2018-06-06
DexTR
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00287872 2018-03-01
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00081939 2017-10-17
UARK 2003-33, Total Therapy III
University of Arkansas
Phase 2 Completed
NCT00222105 2017-07-02
A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
University of Kansas Medical Center
Phase 2 Completed
NCT00182663 2017-06-26
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01548573 2017-06-14
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
Phase 2 Terminated
NCT00523848 2017-02-23
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Roswell Park Cancer Institute
Phase 2 Completed
NCT00040937 2016-12-08
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Completed
NCT00961467 2016-05-10
RMPT
Fondazione EMN Italy Onlus
Phase 2 Completed
NCT01055301 2015-03-06
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00022607 2013-06-24
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00008242 2013-03-07
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00089167 2013-01-16
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00227682 2012-05-28
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00531453 2012-01-26
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT01114048 2011-09-22
KMM-97
Chonnam National University Hospital
Phase 2 Unknown
NCT00577668 2011-05-03
A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)
University of Arkansas
Phase 2 Withdrawn
NCT01341262 2011-04-25
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 2 Completed
NCT01274403 2011-01-11
A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma
Gruppo Italiano Studio Linfomi
Phase 2 Completed
NCT00083681 2010-07-02
DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse
University of Arkansas
Phase 2 Completed
NCT00124813 2010-02-02
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
University Hospital, Bonn
Phase 2 Unknown
NCT00438841 2009-03-13
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00193544 2009-01-23
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00349115 2008-05-06
TCD Followed by autoSCT for Newly Diagnosed MM Patients
Korean Multiple Myeloma Working Party
Phase 2 Unknown
NCT00358020 2006-12-04
Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
University of Turin, Italy
Phase 2 Completed
NCT00319865 2006-04-27
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Korean Multiple Myeloma Working Party
Phase 2 Unknown